Identity & Authority: REVLIMID (Bristol Myers Squibb) – Signal Evidence & AI Readability

REVLIMID (Bristol Myers Squibb)

(https://revlimid.com) 📸 Data Snapshot: June 19, 2026
Identity & Authority — The Lens

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Identity & Authority Expert verifiability & Schema depth.
5 Impact Weight: 15 / 100
33% Reputation

The primary gap is technical rather than reputational. While the company (Bristol Myers Squibb) is a globally recognized authority, the site lacks structured data (schema_json is null) and the heading hierarchy is broken on sub-pages (MDS and MCL pages lack H2-H6 tags entirely). There are no named medical experts linked to Person schema, relying instead on corporate authority.

There is no disconnect because the site makes zero performance claims outside of those cleared by the FDA. Marketing tone is clinical and cautious, focused on ‘indications’ rather than ‘benefits.’ The site demonstrates high substance by providing a comprehensive list of serious side effects and boxed warnings immediately alongside any mention of the drug name.

Identity & Authority is read from the structured data first: whether the site declares who it is in machine-readable schema, with verifiable identity links. Below is the schema captured per page, then the external proof links that support (or fail to support) that identity.

🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps
Homepage — no schema detected (entity gap)
/multiple-myeloma/ — no schema detected (entity gap)
/mds/ — no schema detected (entity gap)
/mcl/ — no schema detected (entity gap)
🛡️ Trust Signals — external proof links that back the declared identity
68Review mentions (all pages)
4External proof links (all pages)
PageReviewsProof links
/ (home) 17 1
/multiple-myeloma/ 17 1
/mds/ 17 1
/mcl/ 17 1
Explore the other reputation pillars for REVLIMID (Bristol Myers Squibb)